https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/665332/Analysis_of_National_Infrastructure_and_Construction_Pipeline_2017.pdf<\/a>. The North-West will receive the highest level of investment of any English ONS region.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
}
, "answeringMemberConstituency" : {"_value" : "Newark"}
, "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
, "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-30T17:56:23.047Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "14"}
, "answeringDeptShortName" : {"_value" : "Treasury"}
, "answeringDeptSortName" : {"_value" : "Treasury"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Infrastructure: Finance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Chancellor of the Exchequer, how much funding his Department plans to allocate to infrastructure development in each region of the Uk in each if the nest two years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4083", "label" : {"_value" : "Biography information for Alison McGovern"}
}
, "tablingMemberConstituency" : {"_value" : "Wirral South"}
, "tablingMemberPrinted" : [{"_value" : "Alison McGovern"}
], "uin" : "182126"}
, {"_about" : "http://data.parliament.uk/resources/992631", "AnsweringBody" : [{"_value" : "Treasury"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/992631/answer", "answerText" : {"_value" : "The government has committed over £1 billion to stimulate the market to build the next generation digital infrastructure the UK needs for the future. At Budget 2018, the government announced £200 million from the National Productivity Investment Fund to pilot innovative approaches to deploying full fibre in rural locations. This follows previous commitments, including the £400 million Digital Infrastructure Investment Fund, the £67 million Gigabit Broadband Voucher Scheme and the £190 million Local Full Fibre Networks Challenge Fund, of which the remaining funds will be allocated to successful bidders in the coming months.<\/p>
<\/p>
The government has also identified around £200 million within the existing Superfast Programme that can further the delivery of full fibre networks.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4320", "label" : {"_value" : "Biography information for Robert Jenrick"}
}
, "answeringMemberConstituency" : {"_value" : "Newark"}
, "answeringMemberPrinted" : {"_value" : "Robert Jenrick"}
, "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-30T17:24:21.077Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "14"}
, "answeringDeptShortName" : {"_value" : "Treasury"}
, "answeringDeptSortName" : {"_value" : "Treasury"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Broadband: Finance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Chancellor of the Exchequer, what funding his Department plans to allocate to the provision of ultra-fast broadband in each region of the UK in each of the next two years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4083", "label" : {"_value" : "Biography information for Alison McGovern"}
}
, "tablingMemberConstituency" : {"_value" : "Wirral South"}
, "tablingMemberPrinted" : [{"_value" : "Alison McGovern"}
], "uin" : "182127"}
, {"_about" : "http://data.parliament.uk/resources/992638", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/992638/answer", "answerText" : {"_value" : "
A six-week postnatal check for all mothers and a six to eight-week check for all babies are not currently specified in the General Medical Services contract as something which general practitioners are required to provide. However, we have asked for the six-week maternal postnatal check, as recommended by the National Childbirth Trust, to be considered in the general practice contract negotiations for 2019/20.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-30T15:53:20.823Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Postnatal Care"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 17 May 2018 to Question 142448 on Postnatal Care, whether the General Medical Services contract sets out that GPs must provide the (a) six week postnatal check for new mothers and (b) six to eight week check for babies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "182198"}
, {"_about" : "http://data.parliament.uk/resources/992639", "AnsweringBody" : [{"_value" : "Northern Ireland Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/992639/answer", "answerText" : {"_value" : "
A decision regarding whether or not to extend the HPV to boys would normally be taken by a Health Minister in Northern Ireland, primarily because of the long-term financial commitments involved. I understand the Department of Health in Northern Ireland intends to keep this position under review.<\/p>
<\/p>
Following the JCVI statement published in July, the Department of Health in Northern Ireland is now undertaking preparatory work to allow for the introduction of HPV to boys in Northern Ireland, if such a decision is taken.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1496", "label" : {"_value" : "Biography information for Shailesh Vara"}
}
, "answeringMemberConstituency" : {"_value" : "North West Cambridgeshire"}
, "answeringMemberPrinted" : {"_value" : "Mr Shailesh Vara"}
, "dateOfAnswer" : {"_value" : "2018-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-29T15:18:40.6Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "21"}
, "answeringDeptShortName" : {"_value" : "Northern Ireland"}
, "answeringDeptSortName" : {"_value" : "Northern Ireland"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Northern Ireland, what the timeframe is for a decision to be made on extending HPV vaccination to adolescent boys in Northern Ireland.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "182199"}
, {"_about" : "http://data.parliament.uk/resources/992640", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/992640/answer", "answerText" : {"_value" : "
To date, the National Institute for Health and Care Excellence (NICE) has recommended all eight medicines that it has evaluated through its highly specialised technologies (HST) programme for some or all of the eligible patient population, in most cases subject to managed access agreements that specify clinical criteria and data collection requirements. National Health Service organisations are legally required to fund medicines recommended in NICE\u2019s HST guidance, and patients with the rare diseases concerned are now benefitting from access to the medicines in line with NICE\u2019s recommendations.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "182202"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-30T15:52:26.797Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Rare Diseases: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent steps he has taken to assess the effect of NICE\u2019s Highly Specialised Technologies process on patients in the UK with rare diseases.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "182200"}
, {"_about" : "http://data.parliament.uk/resources/992641", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/992641/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence has advised that prior to the revised methods for the development of highly specialised technology (HST) evaluation guidance being introduced in 2017, the HST programme did not have a cost-effectiveness framework to inform the consideration of value for money. Therefore it is not possible to confirm if those technologies that were evaluated before April 2017 would have been recommended under the new methods, because the key elements of the new methods were not established and were not considered by the committee in the context of the many other factors taken into account in the decision-making.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-30T15:49:43.26Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Rare Diseases: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether treatments for rare diseases approved under the Highly Specialised Technologies (HST) process would have been rejected under the new criteria introduced for the HST process in 2017.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "182201"}
, {"_about" : "http://data.parliament.uk/resources/992642", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/992642/answer", "answerText" : {"_value" : "
To date, the National Institute for Health and Care Excellence (NICE) has recommended all eight medicines that it has evaluated through its highly specialised technologies (HST) programme for some or all of the eligible patient population, in most cases subject to managed access agreements that specify clinical criteria and data collection requirements. National Health Service organisations are legally required to fund medicines recommended in NICE\u2019s HST guidance, and patients with the rare diseases concerned are now benefitting from access to the medicines in line with NICE\u2019s recommendations.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "182200"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-30T15:52:26.857Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the (a) criteria used for and (b) long term data collection requirement of the highly specialised technologies process.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "182202"}
, {"_about" : "http://data.parliament.uk/resources/992643", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/992643/answer", "answerText" : {"_value" : "
The number of successful individual funding requests since January 2018 is less than 10, and the true figure has been withheld to protect patient confidentiality. The critically urgent criteria process and decision making ceased on publication of the Specialised Commissioning Service Development Policy, which was published by NHS England on 12 September 2017.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-30T15:56:29.653Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Finance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many successful applications there have been (a) to NHS England\u2019s individual funding requests for specialised services and (b) through the clinically critically urgent criteria process since January 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "182203"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-AnswerDate=2018-10-24&writtenParliamentaryQuestionType=Ordinary", "page" : 0, "startIndex" : 1, "totalResults" : 136465, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}